There are currently no approved lipid lowering therapies that specifically target Lp(a).1 Although there have been no randomised controlled trials (RCTs) showing that lowering Lp(a) improves cardiovascular (CV) outcomes,2 PCSK9 inhibitor outcome trials have provided initial data indicating that even small reductions in Lp(a) in secondary prevention can reduce event rates.3,4 Studies with Lp(a) apheresis are not inconsistent with this finding but RCTs have not been carried out to confirm this.
For individuals with elevated Lp(a), the European Atherosclerosis Society (EAS) consensus statement recommends early, intensive management of other risk factors, aligned with European and North American guidelines.1,2,5,6 These include LDL-C, blood pressure, glucose, and lifestyle factors.2,5,6
Please login or create a FREE account to view this content
See more articles in our Back to Basics series
Back to Basics Slide Deck Resource available now
A collection of state-of-the-art slide decks providing an accessible introduction to the growing body of evidence supporting Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, including in individuals with low LDL-cholesterol levels.
